PDUFA VII would support Pfizer's commitment to modernizing the drug development process to make sure that drugs are thoroughly reviewed while ensuring new safe and effective treatments are available for patients. By enhancing FDA's capacity to review innovative treatments, the updated PDUFA would help biopharma companies and regulators become stronger, more efficient, and more patient-centric to advance and deliver tomorrow's scientific breakthroughs.
